PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 322.00
Ask: 325.00
Change: -13.00 (-3.86%)
Spread: 3.00 (0.932%)
Open: 321.00
High: 326.00
Low: 311.00
Prev. Close: 337.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Aug 2019 07:48

RNS Number : 6044J
Hutchison China Meditech Limited
20 August 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 Hutchison China MediTech Limited

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

The Capital Group Companies, Inc. ("CGC")

City and country of registered office (if applicable)

Los Angeles, CA 90071, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

15 August 2019

6. Date on which issuer notified (DD/MM/YYYY):

16 August 2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.0357%

0.0000%

5.0357%

666,577,450

Position of previous notification (if

applicable)

N/A

 

N/A

 

 

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares (ISIN:

KYG4672N1198)

2,651,060

0.3977%

ADRs (ISIN: US44842L1035)

30,915,775

4.6380%

SUBTOTAL 8. A

33,566,835

5.0357%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

The Capital Group Companies, Inc.

Holdings by CG Management companies are set out below:

5.0357%

0.0000%

5.0357%

Capital Bank & Trust Company2

Capital International, Inc.1

Capital International Limited1

Capital International Sàrl1

• Capital Research and Management Company2

1Indirect subsidiaries of Capital Research and Management Company.

2Subsidiary of The Capital Group Companies, Inc.

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of four investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K. CGII management companies and CB&T primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of your company for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

Place of completion

Los Angeles, CA, USA

Date of completion

16 August 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLURSNRKOAWURR
Date   Source Headline
9th Oct 20137:00 amRNSPayment From Janssen Pharmaceuticals
9th Oct 20137:00 amRNSLilly Deal for Fruquintinib
9th Oct 20137:00 amRNSAnalyst & Investor Briefing
3rd Oct 20137:00 amRNSAnalyst briefing on Chi-Med's R&D business
13th Sep 20132:21 pmRNSHolding(s) in Company
8th Aug 201312:05 pmRNSDirector/PDMR Shareholding
30th Jul 20137:00 amRNSInterim Results
17th Jul 20137:00 amRNSGlobal Phase III HPML-004 maintenance study starts
1st Jul 20137:00 amRNSBlocklisting Interim Review
25th Jun 20137:00 amRNSVolitinib Phase I triggers US$5 million milestone
24th Jun 20137:00 amRNSNotice of Results
10th May 201312:24 pmRNSResult of AGM
24th Apr 20137:00 amRNSGlobal Phase III UC trial initiated with HPML-004
12th Apr 20137:16 amRNSNutrition Science Partners JV Approved
9th Apr 20137:00 amRNS2012 Annual Report and Notice of AGM
8th Apr 20137:00 amRNSData Presentations at AACR
26th Mar 20137:00 amRNSFinal Results
28th Feb 20137:00 amRNSTotal Voting Rights
18th Feb 20137:00 amRNSNotice of Results
28th Jan 201311:15 amRNSHolding(s) in Company
31st Dec 20127:00 amRNSBlocklisting Six Monthly Return
28th Nov 20127:00 amRNSChi-Med and Nestle´ Health Science Joint Venture
1st Nov 20127:00 amRNSPhase I trial with EGFR inhibitor theliatinib
8th Oct 20127:00 amRNSTR1 Notification of major interest in shares
28th Sep 20121:42 pmRNSTotal Voting Rights
13th Sep 20122:16 pmRNSDirector's Shareholding
28th Aug 201211:21 amRNSChange of Nominated Adviser
31st Jul 20127:00 amRNSInterim Results
5th Jul 20129:08 amRNSTotal Voting Rights
29th Jun 20127:00 amRNSBlocklisting Interim Review
28th Jun 20127:00 amRNSNotice of Results
14th Jun 20121:33 pmRNSExercise of Options
6th Jun 20127:00 amRNSAnti-Cancer Clinical Data Presented at ASCO
30th May 20121:48 pmRNSDirector/PDMR Shareholding
11th May 201212:32 pmRNSResult of AGM
10th Apr 20127:00 amRNS2011 Annual Report and Notice of AGM
20th Mar 20127:00 amRNSFinal Results
22nd Feb 20127:00 amRNSNovel c-Met inhibitor Volitinib Enters the Clinic
20th Feb 20127:00 amRNSNotice of Results
14th Feb 20128:07 amRNSHolding(s) in Company
2nd Feb 20127:00 amRNSTotal Voting Rights
5th Jan 201210:49 amRNSHolding(s) in Company
29th Dec 20117:00 amRNSBlocklisting Six Monthly Return
21st Dec 20117:00 amRNSCANCER THERAPY COLLABORATION WITH ASTRAZENECA
12th Dec 20117:00 amRNSChi-Med Loan Facility
4th Nov 20117:00 amRNSInitiates Epitinib Phase I clinical study
5th Sep 20117:00 amRNSHolding(s) in Company
1st Aug 20117:00 amRNSInterim Results
22nd Jul 20117:00 amRNSChina Healthcare Division expansion
5th Jul 20117:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.